Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

| introdu | cea 01/07/96 Origin: Appendix 5 Amendea 01/07/98, 0 | 1/09/99,01/07/00,30/09/01,11/03/02,01/01/03,24/10/05,01/08/12,04/03/. |
|---------|---|--|
| Name | of entity | |
| ISEL | ECT LIMITED | |
| | | |
| ABN | | |
| 48 1 | .24 302 932 | |
| We (| the entity) give ASX the following ir | nformation. |
| _ | t 1 - All issues nust complete the relevant sections (attach : | sheets if there is not enough space). |
| 1 | ⁺ Class of ⁺ securities issued or to be issued | Performance Rights |
| 2 | Number of ⁺ securities issued or to be issued (if known) or maximum number which may be issued | 5,570,499 |
| | | |
| 3 | Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion) | The Performance Rights issued to the Executive Director (1,329,032) and other eligible participants (4,241,467) in accordance with the terms of the Company's Performance Rights Plan ("PRP"). The issue of 1,329,032 Performance Rights to the Executive Director was approved by the shareholders at the Annual General Meeting |

04/03/2013 Appendix 3B Page 1

(AGM) held on 24 October 2019.

⁺ See chapter 19 for defined terms.

Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

The Performance Rights will not be quoted or rank equally with any class of ordinary securities of the Company.

The underlying fully paid ordinary shares allocated to the holder upon vesting of the Performance Rights in accordance with the relevant service and performance conditions (unless the Board exercises discretion that a participant's shares vest under the rules of the PRP on a different date) will be quoted on the ASX and will rank equally with all other ordinary shares on issue.

In accordance with the PRP rules, the Performance Rights:

- a. do not carry voting Rights;
- b. do not currently carry rights to dividends;
- c. cannot be sold, transferred, mortgaged, pledged, assigned, alienated or otherwise deal with any interest in unvested Performance Rights; and
- d. will be lapsed if certain service and performance conditions are not met.

| 5 | lssue | price | or | consid | leration |
|---|-------|-------|----|--------|----------|
| | | | | | |

Nil

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) The Performance Rights are issued to the Executive Director and other eligible participants under the Company's Performance Rights Plan for the FY20.

6a Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b – 6h *in relation to the *securities the subject of this Appendix 3B*, and comply with section 6i

No

6b The date the security holder resolution under rule 7.1A was passed

N/A

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

| 6c | Number of *securities issued without security holder approval under rule 7.1 | N/A | |
|----|---|-----------------|----------|
| | | | |
| 6d | Number of *securities issued with security holder approval under rule 7.1A | N/A | |
| | | | |
| 6e | Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) | N/A | |
| | | | |
| 6f | Number of *securities issued under an exception in rule 7.2 | N/A | |
| | | | |
| 6g | If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation. | N/A | |
| | | | |
| 6h | If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements | N/A | |
| | | Γ . | |
| 6i | Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements | N/A | |
| | | | |
| 7 | ⁺ Issue dates | 8 November 2019 | |
| | Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. | | |
| | Cross reference: item 33 of Appendix 3B. | | |
| | | | |
| | | Number | +Class |
| 8 | Number and *class of all | 217,861,393 | Ordinary |
| J | *securities quoted on ASX | 217,001,003 | Cramary |
| | (including the *securities in section 2 if applicable) | | |

⁺ See chapter 19 for defined terms.

9 Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)

| Number | †Class |
|--|--|
| Number | |
| 3,340,609 | LTIP Balance brought forward at 08/11/2019 |
| | Movements in LTIP since last Appendix 3B (20/06/2019) |
| Nil | Issued |
| (2,500,000) (FY19) (250,676) (FY17) | Lapsed & Forfeited |
| Nil | Exercised |
| 589,933 | Balance (current) of LTIP |
| 3,790,831 | Performance Rights Balance brought forward at 08/11/2019 |
| | Movements in Performance Rights since last Appendix 3B (20/06/2019) |
| 5,570,499 (PRP FY20) (751,841) (PRP FY17) (48,491) (PRP FY18) (35,372) (PRP FY19) | Issued Lapsed & Forfeited |
| Nil | Exercised |
| 8,525,626 | Balance (current) of Performance Rights |

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

| N/A | | | |
|-----|--|--|--|
| | | | |

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

Part 2 - Pro rata issue

| 11 | Is security holder approval required? | N/A |
|----|--|-----|
| 12 | Is the issue renounceable or non-renounceable? | N/A |
| 13 | Ratio in which the *securities will be offered | N/A |
| 14 | *Class of *securities to which the offer relates | N/A |
| 15 | *Record date to determine entitlements | N/A |
| 16 | Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? | N/A |
| 17 | Policy for deciding entitlements in relation to fractions | N/A |
| 18 | Names of countries in which the entity has security holders who will not be sent new offer documents | N/A |
| | Note: Security holders must be told how their entitlements are to be dealt with. | |
| | Cross reference: rule 7.7. | |
| 19 | Closing date for receipt of acceptances or renunciations | N/A |

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

| 20 | Names of any underwriters | N/A |
|----|---|-----|
| 21 | Amount of any underwriting fee or commission | N/A |
| 22 | Names of any brokers to the issue | N/A |
| 23 | Fee or commission payable to the broker to the issue | N/A |
| 24 | Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders | N/A |
| 25 | If the issue is contingent on security holders' approval, the date of the meeting | N/A |
| 26 | Date entitlement and acceptance form and offer documents will be sent to persons entitled | N/A |
| 27 | If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders | N/A |
| 28 | Date rights trading will begin (if applicable) | N/A |
| 29 | Date rights trading will end (if applicable) | N/A |
| 30 | How do security holders sell their entitlements <i>in full</i> through a broker? | N/A |
| 31 | How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance? | N/A |

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

| 32 | their | o security holders dispose of entitlements (except by sale that a broker)? | N/A |
|-------------------|---------|--|---|
| 33 | †Issue | date | N/A |
| | | Quotation of securit complete this section if you are appl | |
| 34 | Type o | f ⁺securities ne) | |
| (a) | | *Securities described in Part 1 | |
| (b) | | | of the escrowed period, partly paid securities that become fully paid, employee ends, securities issued on expiry or conversion of convertible securities |
| Entiti | es tha | t have ticked box 34(a) | |
| Additi | onal se | curities forming a new class | s of securities |
| Tick to docume | | you are providing the informat | ion or |
| 35 | | | securities, the names of the 20 largest holders of the number and percentage of additional *securities held |
| 36 | | | r securities, a distribution schedule of the additional aber of holders in the categories |
| 37 | | A copy of any trust deed for th | e additional *securities |

⁺ See chapter 19 for defined terms.

| Entiti | es that have ticked box 34(b) | | |
|--------|--|--------|--------|
| 38 | Number of *securities for which *quotation is sought | | |
| 39 | *Class of *securities for which quotation is sought | | |
| 40 | Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? | | |
| | If the additional *securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment | | |
| 41 | Reason for request for quotation now Example: In the case of restricted securities, end of restriction period | | |
| | (if issued upon conversion of another *security, clearly identify that other *security) | | |
| | | Number | +Class |
| 42 | Number and *class of all *securities quoted on ASX (including the *securities in clause 38) | Number | +Class |
| | | | |

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional *securities is in ASX's absolute discretion. ASX may quote the *securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will
 not require disclosure under section 707(3) or section 1012C(6) of the
 Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

...... Date: 8 November 2019

Company Secretary

Print name: Mark Licciardo

== == == ==

⁺ See chapter 19 for defined terms.